The Phase 1 study of PRT12396 is an open-label, multi-center, safety and efficacy study in patients with high-risk polycythemia vera (PV) and intermediate and high-risk myelofibrosis (MF). The primary ...
Improved outcome for acute lymphoblastic leukemia (ALL) in children and adolescents: Results of the MCP841—A two decades report from a developing country (India) No significant financial relationships ...
The MarketWatch News Department was not involved in the creation of this content. DOVER, Del., Nov. 6, 2025 /PRNewswire/ -- Eilean Therapeutics LLC, a biotechnology company developing next-generation ...
ZRSR2 mutations are linked to JAK2 V617R-driven MPNs but are insufficient alone for disease progression. CRISPR-Cas9 studies showed ZRSR2 loss causes intron retention and transcriptional changes ...
Chronic myeloid leukaemia (CML) is a paradigmatic clonal disorder primarily driven by the BCR-ABL translocation, which produces a constitutively active tyrosine kinase. Traditionally, this genetic ...
Researchers from Incyte Corp. and collaborators presented the preclinical profile of INCB-160058, an ATP-competitive small-molecule inhibitor of the JAK2 V617F mutant sparing its wild-type (WT) form, ...
The MarketWatch News Department was not involved in the creation of this content. DOVER, Del., Dec. 17, 2025 /PRNewswire/ -- Eilean Therapeutics announced the advancement of ZE74-0282 into ...
Researchers from Bulgaria conduct an analysis of the potential for therapeutic vaccines in by comparing testing results for patients from their country with an international data set. Mutations may ...
Myeloproliferative neoplasms (MPNs) represent a cluster of conditions characterized by the excessive production of blood cells within the bone marrow. Among MPN patients, abnormal quantities of red ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results